Differences in chemosensitivity between primary and paired metastatic lung cancer tissues: In vitro analysis based on the collagen gel droplet embedded culture drug test (CD-DST) - PubMed (original) (raw)
Differences in chemosensitivity between primary and paired metastatic lung cancer tissues: In vitro analysis based on the collagen gel droplet embedded culture drug test (CD-DST)
Masahiko Higashiyama et al. J Thorac Dis. 2012 Feb.
Abstract
Background: To elucidate the differences in chemosensitivity to anticancer drugs between primary and metastatic lesions in non-small cell lung cancer (NSCLC) patients, we examined the in vitro chemosensitivities of surgically resected NSCLC tissues.
Methods: A total of 32 specimens were enrolled: 26 specimens of primary lesions paired with metastases in the lymph node, 3 specimens of primary lesions paired with metastases in the adrenal gland, and 3 specimens of primary lesions paired with metastases in the lung. The collagen gel droplet embedded culture drug test (CD-DST) was applied to examine the sensitivity of the tissues to anticancer drugs, including cisplatin, gemcitabine, vinorelbine, docetaxel and 5-fluorouracil.
Results: The degree of in vitro sensitivity to each anticancer drug varied between the primary and metastatic lesions. The sensitivity of the paired metastatic lesions was significantly lower than that of the primary lesions only for gemcitabine (P=0.029), vinorelbine (P=0.012), and docetaxel (P=0.009). The incidence of cases diagnosed as CD-DST-sensitive among the paired metastatic lesions was significantly lower than that for the primary lesions for vinorelbine (P=0.035) or docetaxel (P=0.022). The difference in the sensitivity to gemcitabine between the primary and paired non-lymphatic metastases was clearer than that between the primary lesion and paired lymph node metastases.
Conclusions: The sensitivities of the paired metastatic lesions to some anticancer drugs were significantly lower than those of the primary lesions. When performing chemotherapy based on CD-DST data using primary tumors from patients with postoperative recurrence, an appropriate regimen can be selected by carefully considering these differences.
Keywords: Non-small cell lung cancer (NSCLC); chemosensitivity test; chemotherapy; collagen gel droplet embedded culture drug test (CD-DST); metastatic tissue.
Conflict of interest statement
No potential conflict of interest.
Figures
Figure 1.. Comparison of the in vitro chemosensitivities (T/C ratio, %) of primary lesions and their paired metastatic NSCLC lesions.
P: primary lesions, M: paired metastatic lesions. The cases surrounded with dotted-line frames were diagnosed as being in vitro-sensitive. The P value for each anticancer drug was calculated using the Paired T test. Fig 1. shows a comparison of CD-DST data between each primary lesion and its paired metastatic lesion for each anticancer drug. For GEM, VNR, and TXT, the T/C ratio of the metastatic lesions was significantly higher than that of the primary lesions. In contrast, for CDDP and 5-FU, no significant differences in chemosensitivity were observed.
Figure 2.. Differences in the T/C ratio (%) between the primary lesions and their paired metastatic lesions.
Differences in the T/C ratio (%) between the primary lesions and their paired metastatic lesions are shown by waterfall plots. The black columns show the difference between primary lesions and their paired lymph node lesion. The white columns show the difference between primary lesions and their paired non-lymphatic lesions. Although the cases involving a non-lymphatic route (white column) were widely distributed, 4 cases (67%) treated with GEM showed a 30% or greater increase in in vitro resistance in the paired metastatic lesions compared with the primary tissue. Three cases (50%) showed similar results for CDDP.
Similar articles
- Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients.
Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Imamura F, Minamikawa K, Takano T, Kobayashi H. Higashiyama M, et al. Lung Cancer. 2010 Jun;68(3):472-7. doi: 10.1016/j.lungcan.2009.07.005. Epub 2009 Aug 5. Lung Cancer. 2010. PMID: 19660825 - Chemosensitivity of lung cancer: Differences between the primary lesion and lymph node metastasis.
Maniwa Y, Yoshimura M, Hashimoto S, Takata M, Nishio W. Maniwa Y, et al. Oncol Lett. 2010 Mar;1(2):345-349. doi: 10.3892/ol_00000061. Epub 2010 Mar 1. Oncol Lett. 2010. PMID: 22966306 Free PMC article. - In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application.
Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Takami K, Morinaga K, Takano T, Kobayashi H. Higashiyama M, et al. Ann Thorac Cardiovasc Surg. 2008 Dec;14(6):355-62. Ann Thorac Cardiovasc Surg. 2008. PMID: 19131921 - A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. Clegg A, et al. Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068 Review. - Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness.
Kobayashi H. Kobayashi H. Recent Results Cancer Res. 2003;161:48-61. doi: 10.1007/978-3-642-19022-3_5. Recent Results Cancer Res. 2003. PMID: 12528798 Review.
Cited by
- A PDX model combined with CD-DST assay to evaluate the antitumor properties of KRpep-2d and oxaliplatin in KRAS (G12D) mutant colorectal cancer.
Li W, Chen W, Wang J, Zhao G, Chen L, Wan Y, Luo Q, Li W, Huang H, Li W, Li W, Yang Y, Chen D, Su Q. Li W, et al. Heliyon. 2022 Dec 21;8(12):e12518. doi: 10.1016/j.heliyon.2022.e12518. eCollection 2022 Dec. Heliyon. 2022. PMID: 36590511 Free PMC article. - Radiosensitivity of Breast Cancer Cells Is Dependent on the Organ Microenvironment.
Guo G, Morse RT, Wang J, Chen X, Zhang J, Wang AZ. Guo G, et al. Front Oncol. 2022 May 12;12:833894. doi: 10.3389/fonc.2022.833894. eCollection 2022. Front Oncol. 2022. PMID: 35646713 Free PMC article. - Outcomes of Mixed Pathologic Response in Patients with Multiple Colorectal Liver Metastases Treated with Neoadjuvant Chemotherapy and Liver Resection.
Mason MC, Krasnodebski M, Hester CA, Kothari AN, Barker C, Nishioka Y, Chiang YJ, Newhook TE, Tzeng CD, Chun YS, Vauthey JN, Tran Cao HS. Mason MC, et al. Ann Surg Oncol. 2022 Aug;29(8):5156-5164. doi: 10.1245/s10434-022-11683-1. Epub 2022 Apr 10. Ann Surg Oncol. 2022. PMID: 35397746 - Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.
Morand du Puch CB, Vanderstraete M, Giraud S, Lautrette C, Christou N, Mathonnet M. Morand du Puch CB, et al. Theranostics. 2021 Sep 21;11(19):9538-9556. doi: 10.7150/thno.55954. eCollection 2021. Theranostics. 2021. PMID: 34646385 Free PMC article. Review. - Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.
Tian X, Werner ME, Roche KC, Hanson AD, Foote HP, Yu SK, Warner SB, Copp JA, Lara H, Wauthier EL, Caster JM, Herring LE, Zhang L, Tepper JE, Hsu DS, Zhang T, Reid LM, Wang AZ. Tian X, et al. Nat Biomed Eng. 2018 Jun;2(6):443-452. doi: 10.1038/s41551-018-0231-0. Epub 2018 Apr 23. Nat Biomed Eng. 2018. PMID: 31011191 Free PMC article.
References
- Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317–23. - PubMed
- Akamine S, Nakamura Y, Oka T, Soda H, Taniguchi H, Fukuda M, et al. Induction chemotherapy with cisplatin, vinorelbine, and mitomycin-C followed by surgery for patients with pathologic N2 non-small-cell lung cancer. Clin Lung Cancer. 2008;9:44–50. - PubMed
- Kern DH. Heterogeneity of drug resistance in human breast and ovarian cancers. Cancer J Sci Am. 1998;4:41–5. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources